Skip to main content

News Releases

IDEAYA Biosciences Welcomes Spelman College Interns

South San Francisco, CA, May 3, 2022 – IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced participants in its Spelman College summer intern program for 2022.

We are excited to welcome three scholars from our academic partner, Spelman College, to IDEAYA Biosciences this summer! 

Our partnership with Spelman College was initiated in 2020, when we began discussing how we can be impactful to young professionals with an interest in biotechnology and healthcare. We created a program that will allow select students at Spelman to receive life-changing experiences working in our labs and offices alongside our employees . In addition to the interactive component of the program, each student chosen will also receive an IDEAYA-sponsored scholarship award for their Junior and Senior years. Our hope is to encourage young minds to grow and flourish while gaining valuable industry experience, and we have no doubt that will happen over the course of the program.

Meet our Scholars for Summer 2022:

Chelsea Weaver – Class of 2023, Biology Major
Jasmine Freeman – Class of 2024, Biology Major
Nya Brown – Class of 2023, Health Science Major

About IDEAYA Biosciences
IDEAYA is a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.  IDEAYA’s approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies.  IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets. 

Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA’s Annual Report on Form 10-K filed on March 18, 2022 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.


Investor and Media Contact
IDEAYA Biosciences
Paul Stone
Senior Vice President and Chief Financial Officer

Close Menu